Merck KGaA (MKGAF) reports robust Q4 results with significant growth across sectors, despite challenges in Life Science and ...
Q4 2024 Earnings Call Transcript March 11, 2025 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...
Clinical Trials Arena on MSN3d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look ...
Quantum-Si aims to revolutionize protein sequencing amidst technological hurdles, uncertain advancements, and market ...
Q4 2024 Earnings Call Transcript March 6, 2025 CytomX Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.22, ...
SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...
On March 4, 2025, filings revealed that CEO Stephane Bancel purchased 160,314 shares of MRNA stock between $31.04 and $31.53, ...
Institutional investing is a key measure that retail investors can use to gauge market sentiment on an individual stock or ...
Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") of a class action securities lawsuit. CLASS ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback